# RNN 1st Gen Model DaVita healthCare Partners Inc. Miscellaneous health & allied services, not elsewhere classified

Stock predictor AI models:
81.43% successful of 70 deals
$ 111.84 Last close price
at 18-oct-2021


Model's trade recommendations -3.59% Return for period

-0.90% Annual return

$11.12B Market Cap

β 1.10  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period -3.59%
52wk return -11.79%
52wk Range
Sortino ratio 0.06
Sharpe ratio 0.05
Norm. RMSE 0.82%
Downside risk 18.02%
Volatility 0.00%
  • BUY Analysts consensus recommendation

DaVita Inc. is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a provider of kidney care, delivering dialysis services for chronic kidney failure and end stage renal disease primarily in the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks primarily in California, Nevada, New Mexico, Florida, Colorado and Washington. DaVita Inc., formerly known as DaVita HealthCare Partners Inc., is headquartered in Denver, Colorado.

Industry sector: Medical

Sector classification: Miscellaneous health & allied services, not elsewhere classified

Deep Learning based analysis and prediction model for DaVita healthCare Partners Inc. (DVA) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for DVA model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for DVA.

Model is being retrained on a daily basis.

Float 172M
P/E 18.42
Shares Outstanding 175M
% Held by Insiders 2.10%
% Held by Institutions 85.45%
EPS (last reported FY) $3.32
EPS (last reported Q) $0.92
EPS, estimated (last reported Q) $0.91
Total revenues $11 B
Net income $1 B